Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach
dc.contributor.author | Dublang Irazabal, Leire | |
dc.contributor.author | Underhaug, Jarl | |
dc.contributor.author | Flydal, Marte I. | |
dc.contributor.author | Velasco Carneros, Lorea | |
dc.contributor.author | Maréchal, Jean-Didier | |
dc.contributor.author | Moro Pérez, Fernando | |
dc.contributor.author | Boyano López, María Dolores | |
dc.contributor.author | Martinez, Aurora | |
dc.contributor.author | Muga Villate, Arturo | |
dc.date.accessioned | 2021-07-13T06:56:48Z | |
dc.date.available | 2021-07-13T06:56:48Z | |
dc.date.issued | 2021-06-11 | |
dc.identifier.citation | Cancers 13(12) : (2021) // Article ID 2936 | es_ES |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | http://hdl.handle.net/10810/52446 | |
dc.description.abstract | Heat shock protein (Hsp) synthesis is upregulated in a wide range of cancers to provide the appropriate environment for tumor progression. The Hsp110 and Hsp70 families have been associated to cancer cell survival and resistance to chemotherapy. In this study, we explore the strategy of drug repurposing to find new Hsp70 and Hsp110 inhibitors that display toxicity against melanoma cancer cells. We found that the hits discovered using Apg2, a human representative of the Hsp110 family, as the initial target bind also to structural regions present in members of the Hsp70 family, and therefore inhibit the remodeling activity of the Hsp70 system. One of these compounds, the spasmolytic agent pinaverium bromide used for functional gastrointestinal disorders, inhibits the intracellular chaperone activity of the Hsp70 system and elicits its cytotoxic activity specifically in two melanoma cell lines by activating apoptosis. Docking and molecular dynamics simulations indicate that this compound interacts with regions located in the nucleotide-binding domain and the linker of the chaperones, modulating their ATPase activity. Thus, repurposing of pinaverium bromide for cancer treatment appears as a promising novel therapeutic approach. | es_ES |
dc.description.sponsorship | This study was funded by grants BFU2016-75983-P and PID2019-111068GB-100 (AEI/FEDER/UE) from MINECO to F.M. and A.M. (Arturo Muga) and IT1201-19 from the Basque Government to F.M. Support from the Research Council of Norway (RCN, Grant FRIMEDBIO 261826/F20), the Western Norway Regional Health Authority (912246 to A.M. (Aurora Martinez) and M.I.F.), the infrastructure projects NOR-Openscreen (RCN) and EU-Openscreen, and the use of the core facility BiSS, University of Bergen, are acknowledged. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/BFU2016-75983-P | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/PID2019-111068GB-100 | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject | chaperones | es_ES |
dc.subject | drug repurposing | es_ES |
dc.subject | inhibitors | es_ES |
dc.subject | melanoma | es_ES |
dc.subject | pinaverium bromide | es_ES |
dc.title | Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2021-06-24T14:11:48Z | |
dc.rights.holder | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/2072-6694/13/12/2936 | es_ES |
dc.identifier.doi | 10.3390/cancers13122936 | |
dc.departamentoes | Bioquímica y biología molecular | |
dc.departamentoes | Biología celular e histología | |
dc.departamentoeu | Biokimika eta biologia molekularra | |
dc.departamentoeu | Zelulen biologia eta histologia |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).